Eisbach Bio develops drugs for serious diseases such as cancer. The Munich-based biotech company, based in Biotechnology Innovation and Start-up Center (IZB) in Martinsried is also working on a targeted drug for the SARS-CoV-2 enzyme Nsp13. The Federal Ministry is now supporting the clinical validation of the drug. Eisbach's CEO, Adrian Schomburg, says:
"We are very grateful for the BMBF's support in the clinical validation of our drug candidate, which would enable convenient oral administration. Because the tablets can be easily manufactured and shipped, our drug candidate offers broad potential not only to alleviate disease symptoms but also to reduce the number of COVID-19 hospitalizations and deaths worldwide."
Clinical trials for Eisbach Bio's COVID drug to start in the first quarter of 2022
The Eisbach CSO Andreas Ladurner says:
"Our drug blocks viral replication through a novel mechanism that is fully conserved across all known virus variants. We are committed to developing a sustainable drug with a good safety profile that should enable the treatment of all individuals who test positive for SARS-CoV-2, especially high-risk patients."
The company expects to begin Phase I clinical trials for its COVID-19 drug in the first quarter of 2022.
"We are very proud that top researchers from the Bavarian Silicon Valley will also be contributing to meeting the high medical need for effective COVID-19 drugs. Congratulations to the team led by Dr. Adrian Schomburg and Prof. Andreas Ladurner from Eisbach Bio on receiving funding from the Federal Ministry of Education and Research (BMBF)."
says Peter Hanns Zobel, Managing Director of the IZB.
